259 related articles for article (PubMed ID: 26172306)
1. Biomarkers, the control panel and personalized COPD medicine.
Agusti A; Gea J; Faner R
Respirology; 2016 Jan; 21(1):24-33. PubMed ID: 26172306
[TBL] [Abstract][Full Text] [Related]
2. Clinical and molecular markers in COPD.
Gonçalves I; Guimarães MJ; van Zeller M; Menezes F; Moita J; Simão P;
Pulmonology; 2018; 24(4):250-259. PubMed ID: 29898875
[TBL] [Abstract][Full Text] [Related]
3. Moving towards a Treatable Traits model of care for the management of obstructive airways diseases.
Agusti A; Barnes N; Cruz AA; Gibson PG; Heaney LG; Inoue H; Leather D; Martinez FJ; McDonald VM; Oppenheimer J; Papi A; Pavord ID; Thomas M; Walker S; Yates L
Respir Med; 2021 Oct; 187():106572. PubMed ID: 34478992
[TBL] [Abstract][Full Text] [Related]
4. [PERSONALIZED MEDICINE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT].
Corhay JL
Rev Med Liege; 2015; 70(5-6):310-5. PubMed ID: 26285458
[TBL] [Abstract][Full Text] [Related]
5. The COPD control panel: towards personalised medicine in COPD.
Agusti A; MacNee W
Thorax; 2013 Jul; 68(7):687-90. PubMed ID: 23117977
[TBL] [Abstract][Full Text] [Related]
6. Precision medicine and treatable traits in chronic airway diseases - where do we stand?
Ulrik CS; Vijverberg S; Hanania NA; Diamant Z
Curr Opin Pulm Med; 2020 Jan; 26(1):33-39. PubMed ID: 31644440
[TBL] [Abstract][Full Text] [Related]
7. Personalized medicine for patients with COPD: where are we?
Franssen FM; Alter P; Bar N; Benedikter BJ; Iurato S; Maier D; Maxheim M; Roessler FK; Spruit MA; Vogelmeier CF; Wouters EF; Schmeck B
Int J Chron Obstruct Pulmon Dis; 2019; 14():1465-1484. PubMed ID: 31371934
[TBL] [Abstract][Full Text] [Related]
8. The Challenges of Precision Medicine in COPD.
Cazzola M; Calzetta L; Rogliani P; Matera MG
Mol Diagn Ther; 2017 Aug; 21(4):345-355. PubMed ID: 28247183
[TBL] [Abstract][Full Text] [Related]
9. Personalized medicine and chronic obstructive pulmonary disease.
Wouters EF; Wouters BB; Augustin IM; Franssen FM
Curr Opin Pulm Med; 2017 May; 23(3):241-246. PubMed ID: 28257315
[TBL] [Abstract][Full Text] [Related]
10. Multilevel, Dynamic Chronic Obstructive Pulmonary Disease Heterogeneity. A Challenge for Personalized Medicine.
Faner R; Agustí Á
Ann Am Thorac Soc; 2016 Dec; 13 Suppl 2():S466-S470. PubMed ID: 28005422
[TBL] [Abstract][Full Text] [Related]
11. Blood and sputum protein biomarkers for chronic obstructive pulmonary disease (COPD).
Moon JY; Leitao Filho FS; Shahangian K; Takiguchi H; Sin DD
Expert Rev Proteomics; 2018 Nov; 15(11):923-935. PubMed ID: 30362838
[TBL] [Abstract][Full Text] [Related]
12. The Promise of Observational Studies (ECLIPSE, SPIROMICS, and COPDGene) in Achieving the Goal of Personalized Treatment of Chronic Obstructive Pulmonary Disease.
Rennard SI
Semin Respir Crit Care Med; 2015 Aug; 36(4):478-90. PubMed ID: 26238636
[TBL] [Abstract][Full Text] [Related]
13. Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.
Singh D; Roche N; Halpin D; Agusti A; Wedzicha JA; Martinez FJ
Am J Respir Crit Care Med; 2016 Sep; 194(5):541-9. PubMed ID: 27585383
[TBL] [Abstract][Full Text] [Related]
14. Current Approaches for Phenotyping as a Target for Precision Medicine in COPD Management.
Lopez-Campos JL; Centanni S
COPD; 2018 Apr; 15(2):108-117. PubMed ID: 29558165
[TBL] [Abstract][Full Text] [Related]
15. Personalizing and targeting therapy for COPD: the role of molecular and clinical biomarkers.
Goh F; Shaw JG; Savarimuthu Francis SM; Vaughan A; Morrison L; Relan V; Marshall HM; Dent AG; O'Hare PE; Hsiao A; Bowman RV; Fong KM; Yang IA
Expert Rev Respir Med; 2013 Dec; 7(6):593-605. PubMed ID: 24160750
[TBL] [Abstract][Full Text] [Related]
16. What does endotyping mean for treatment in chronic obstructive pulmonary disease?
Agustí A; Celli B; Faner R
Lancet; 2017 Sep; 390(10098):980-987. PubMed ID: 28872030
[TBL] [Abstract][Full Text] [Related]
17. [Expert Meeting on COPD: Personalized Treatment of COPD - Wishful Thinking or Reality?].
Lorenz J; Bals R; Ewert R; Jany B; Koczulla AR; Köhnlein T; Randerath WJ; Steinkamp G; Watz H; Welte T
Pneumologie; 2016 Oct; 70(10):638-650. PubMed ID: 27723914
[TBL] [Abstract][Full Text] [Related]
18. An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?
Cazzola M; Rogliani P; Puxeddu E; Ora J; Matera MG
Expert Rev Respir Med; 2018 Jan; 12(1):43-54. PubMed ID: 29082808
[TBL] [Abstract][Full Text] [Related]
19. [Personalised COPD care: Where are we going?].
Roche N; Martin C; Burgel PR
Rev Pneumol Clin; 2018 Oct; 74(5):315-326. PubMed ID: 30316649
[TBL] [Abstract][Full Text] [Related]
20. Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?
Hoogendoorn M; Feenstra TL; Asukai Y; Briggs AH; Borg S; Dal Negro RW; Hansen RN; Jansson SA; Leidl R; Risebrough N; Samyshkin Y; Wacker ME; Rutten-van Mölken MPMH
Value Health; 2016; 19(6):800-810. PubMed ID: 27712708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
